Eli Lilly and CompanyvsEntrada Therapeutics

LLY and TRDA stock compared: price, dividend, valuation and results, from SEC filings.

LLY

Eli Lilly and Company

$1,431.67

Value $1.35T

-0.82%
LLY's page

TRDA

Entrada Therapeutics, Inc.

$5.00

Value $191M

-1.77%
TRDA's page

Eli Lilly and Company (LLY) has a market value of $1.35T and Entrada Therapeutics (TRDA) $191M. Over the last year, with dividends, LLY moved +40.5% and TRDA -42.9%. Dividend yield: LLY 0.44%, TRDA none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    LLY$1.35T

    TRDA$191M

    LLY is 7,056 times TRDA

  • Revenue, 12 months

    LLY$86.5B

    TRDA$4.0M

    LLY is 21,740 times TRDA

  • Net income, 12 months

    LLY$27.6B

    TRDA-$161M

  • Operating margin

    LLY–

    TRDA-4,303.8%

  • ROIC

    LLY35.5%

    TRDA-50.1%

    85.6 points apart

  • P/E

    LLY49.0

    TRDA–

  • Dividend yield

    LLY0.4%

    TRDA0.0%

    0.4 points apart

  • 5-year return

    LLY+478.4%

    TRDA-85.5%

    563.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

LLY+478.4%

TRDA-85.5%

020040060020222023202420252026
Returns by period
PeriodLLYWith dividendsTRDAWith dividends
1 year since November 14, 2025+40.5%Price +39.6%-42.9%Price -42.9%
3 years since November 16, 2023+148.1%+35.4% a yearPrice +143.2%-67.5%-31.2% a yearPrice -67.5%
5 years since November 15, 2021+478.4%+42.1% a yearPrice +454.0%-85.5%-32.0% a yearPrice -85.5%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

LLYEli Lilly and CompanyTRDAEntrada Therapeutics

Valuation

LLYTRDA
Valuation
Price$1,431.67$5.00
Market value$1.35T$191M
Enterprise value (EV)$1.40T–
P/E49.0–
P/E, 5-year median49.9–
P/B33.51.0
EV/EBIT40.1–
Free cash flow yield1.5%–

Results and growth

LLYTRDA
Results and growth
Revenue, 12 months$86.5B$4.0M
Net income, 12 months$27.6B-$161M
Free cash flow, 12 months$19.7B-$136M
Earnings per share, 12 months$30.81-$3.84
Revenue growth, year on year44.7%-87.9%
Revenue growth a year, past+21.6%over 5 years-55.6%over 2 years
EPS growth a year, past+27.6%over 5 years–

Margins and returns on capital

LLYTRDA
Margins and returns on capital
Gross margin83.6%–
Operating margin–-4,303.8%
Net margin31.9%-4,058.0%
ROIC35.5%-50.1%
ROE88.6%-59.8%

Balance sheet

LLYTRDA
Balance sheet
Cash$4.9B$193M
Total debt$49.5B$47M
Net debt / EBITDA1.2–
Interest cover38.9×–

Dividends and buybacks

LLYTRDA
Dividends and buybacks
Dividend yield0.4%–
Dividend per share, 12 months$6.34–
Dividend growth a year, past+15.2%over 5 years–
Buyback yield0.3%–
Shareholder yield0.7%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: LLY or TRDA

Didn't find what you were looking for?

Ask us
Which is bigger, Eli Lilly and Company or Entrada Therapeutics?

By market value, Eli Lilly and Company ($1.35T) is about 7,055.5 times Entrada Therapeutics ($191M), at today's prices.

How did LLY and TRDA stock do over the last 5 years?

Since November 15, 2021, LLY's price moved +454.0% and TRDA's -85.5%. With dividends: LLY +478.4% (+42.1% a year), TRDA -85.5% (-32.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, LLY or TRDA?

The dividend yield at today's price is 0.44% for Eli Lilly and Company and none for Entrada Therapeutics. Over the last twelve months they paid $6.34 and – per share.

Which has the higher profit margins, Eli Lilly and Company or Entrada Therapeutics?

Over the last twelve months, the net margin was 31.9% for Eli Lilly and Company and -4,058.0% for Entrada Therapeutics, and the operating margin – and -4,303.8%. Revenue was $86.5B and $4.0M.

Which is the better investment, Eli Lilly and Company or Entrada Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.